Last reviewed · How we verify
Transdermal Scopolamine
Transdermal scopolamine blocks muscarinic acetylcholine receptors to reduce motion sickness and nausea by decreasing vestibular sensitivity and gastric motility.
Transdermal scopolamine blocks muscarinic acetylcholine receptors to reduce motion sickness and nausea by decreasing vestibular sensitivity and gastric motility. Used for Prevention of motion sickness, Prevention of nausea and vomiting associated with travel.
At a glance
| Generic name | Transdermal Scopolamine |
|---|---|
| Sponsor | Repurposed Therapeutics, Inc. |
| Drug class | Anticholinergic agent |
| Target | Muscarinic acetylcholine receptor (M1) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Neurology |
| Phase | FDA-approved |
Mechanism of action
Scopolamine is an anticholinergic agent that crosses the blood-brain barrier and antagonizes M1 muscarinic receptors in the chemoreceptor trigger zone and vestibular nuclei. By suppressing these cholinergic pathways, it prevents the neural signals that trigger nausea and vomiting. The transdermal formulation provides sustained delivery over several days, making it particularly effective for prevention of motion sickness during travel.
Approved indications
- Prevention of motion sickness
- Prevention of nausea and vomiting associated with travel
Common side effects
- Dry mouth
- Drowsiness
- Blurred vision
- Dizziness
- Mydriasis (dilated pupils)
- Urinary retention
Key clinical trials
- Toward a Computationally-Informed, Personalized Treatment for Hallucinations (EARLY_PHASE1)
- Multimodal Analgesia vs. Routine Care Pain Management for Lumbar Spine Fusion Surgery: A Prospective Randomized Study (PHASE4)
- Does IV Magnesium Improve Quality of Recovery With ERAS Protocols in Laparoscopic Colorectal Surgery? (PHASE3)
- Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy (PHASE4)
- A Novel Usage of Transdermal Scopolamine in Reducing Narcotic Usage in Outpatient Hand Surgery
- Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness (PHASE3)
- Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness (PHASE3)
- Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean-Going Vessels (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Transdermal Scopolamine CI brief — competitive landscape report
- Transdermal Scopolamine updates RSS · CI watch RSS
- Repurposed Therapeutics, Inc. portfolio CI